Altimmune Inc.’s ability to start clinical trials for its coronavirus vaccine candidate now lies in the hands of regulators.

The Gaithersburg biotech has submitted its investigational new drug application for its intranasal Covid-19 vaccine, AdCovid, to the Food and Drug Administration, the company said Wednesday. An approval would allow the company to initiate a phase 1 study of the candidate.

Altimmune (NASDAQ: ALT) is on track to kick off that trial in 2020 and report data in the first quarter of 2021, said President and CEO Vipin Garg in a statement. Based on that data, the company “would plan to move swiftly” into a phase 2 clinical trial next year, he told us previously.

Read the full article at: www.bizjournals.com

The following two tabs change content below.
My Twitter profileMy LinkedIn profileMy YouTube channel

Chris Frew

President, CEO at Biobuzz Media & Workforce Genetics
Over the past 8 years, Chris has grown BioBuzz into a respected brand that is recognized for its community building, networking events and news stories about the local biotech industry. In addition, he runs a Recruiting and Marketing Agency that helps companies attract top talent through a blended model that combines employer branding and marketing services together with a high powered recruiting solution.

Related Articles

Emergent BioSolutions Expanding Quality Assurance Team

Emergent BioSolutions Expanding Quality Assurance Team

TEDCO’s MII invested $1.8M in 12 companies and over $4.4M awarded to 36 project grants

TEDCO’s MII invested $1.8M in 12 companies and over $4.4M awarded to 36 project grants

Children’s National Research & Innovation Campus Welcomes New Resident Company, AlgometRx to JLABS @ Washington, DC Site

Children’s National Research & Innovation Campus Welcomes New Resident Company, AlgometRx to JLABS @ Washington, DC Site